You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePantoprazole
Accession NumberDB00213  (APRD00073)
TypeSmall Molecule
GroupsApproved
DescriptionPantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
Structure
Thumb
Synonyms
Pantoprazol
Pantoprazolum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-pantoprazoleTablet, delayed release20 mgOralAbbott Laboratories, LimitedNot applicableNot applicableCanada
Abbott-pantoprazoleTablet, delayed release40 mgOralAbbott Laboratories, Limited2014-03-172015-12-31Canada
Act PantoprazoleTablet, delayed release40 mgOralActavis Pharma Company2008-06-04Not applicableCanada
Auro-pantoprazoleTablet, delayed release40 mgOralAuro Pharma Inc2016-02-06Not applicableCanada
Ava-pantoprazoleTablet, delayed release40 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-pantoprazoleTablet, delayed release20 mgOralAvanstra Inc2011-09-192014-08-21Canada
Bio-pantoprazoleTablet, delayed release40 mgOralBiomed PharmaNot applicableNot applicableCanada
Controloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Controloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Controloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Controloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Dom-pantoprazolePowder, for solution40 mgIntravenousDominion PharmacalNot applicableNot applicableCanada
Dom-pantoprazoleTablet, delayed release20 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-pantoprazoleTablet, delayed release40 mgOralDominion Pharmacal2012-10-25Not applicableCanada
Ipg-pantoprazoleTablet, delayed release40 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-pantoprazoleTablet, delayed release20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-pantoprazoleTablet, delayed release40 mgOralJamp Pharma Corporation2014-12-12Not applicableCanada
Jamp-pantoprazoleTablet, delayed release20 mgOralJamp Pharma Corporation2014-02-11Not applicableCanada
Mar-pantoprazoleTablet, delayed release40 mgOralMarcan Pharmaceuticals Inc2014-07-18Not applicableCanada
Mar-pantoprazoleTablet, delayed release20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pantoprazoleTablet, delayed release40 mgOralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-pantoprazoleTablet, delayed release20 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-pantoprazoleTablet, delayed release40 mgOralMylan Pharmaceuticals Ulc2008-06-03Not applicableCanada
Mylan-pantoprazole TTablet, delayed release40 mgOralMylan Pharmaceuticals Ulc2015-08-31Not applicableCanada
Ntp-pantoprazoleTablet, delayed release20 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-pantoprazoleTablet, delayed release40 mgOralNt Pharma Canada LtdNot applicableNot applicableCanada
Pantecta ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantecta ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantecta ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantecta ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Panto IVPowder, for solution40 mgIntravenousTakeda Canada Inc1999-04-06Not applicableCanada
Panto-bykTablet, delayed release40 mgOralNycomed GmbhNot applicableNot applicableCanada
Panto-bykTablet, delayed release20 mgOralNycomed GmbhNot applicableNot applicableCanada
PantolocTablet, delayed release20 mgOralTakeda Canada Inc2000-05-02Not applicableCanada
PantolocTablet, delayed release40 mgOralTakeda Canada Inc1997-03-05Not applicableCanada
Pantoloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantoloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantoloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantoloc ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
PantoprazoleTablet, delayed release20 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
PantoprazoleTablet, delayed release40 mgOralLaboratoire Riva Inc2014-10-16Not applicableCanada
PantoprazoleTablet, delayed release40 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
PantoprazoleTablet, delayed release40 mgOralSanis Health Inc2011-09-13Not applicableCanada
PantoprazoleTablet, delayed release40 mgOralPharmascience Inc2015-05-20Not applicableCanada
PantoprazoleTablet, delayed release20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
PantoprazoleTablet, delayed release40 mgOralPro Doc Limitee2009-01-29Not applicableCanada
PantoprazoleTablet, delayed release20 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
PantoprazoleTablet, delayed release40 mgOralDominion Pharmacal2015-10-30Not applicableCanada
PantoprazoleTablet, delayed release20 mgOralMeliapharm Inc2009-08-282014-06-25Canada
PantoprazoleTablet, delayed release40 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
PantoprazoleTablet, delayed release40 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
PantoprazoleTablet, delayed release40 mgOralMeliapharm Inc2009-08-282014-06-25Canada
PantoprazoleTablet, delayed release40 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pantoprazole for InjectionPowder, for solution40 mgIntravenousAuro Pharma IncNot applicableNot applicableCanada
Pantoprazole for InjectionPowder, for solution40 mgIntravenousTeva Canada Limited2010-05-17Not applicableCanada
Pantoprazole for InjectionPowder, for solution40 mgIntravenousFresenius Kabi Canada Ltd2010-12-14Not applicableCanada
Pantoprazole MagnesiumTablet, delayed release40 mgOralAspri Pharma Canada Inc2015-11-25Not applicableCanada
Pantoprazole Sodium Delayed ReleaseTablet, delayed release20 mg/1OralSTAT Rx USA LLC2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release40 mg/1OralPreferred Pharmaceuticals, Inc.2014-02-06Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release20 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release40 mg/1OralCardinal Health2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release40 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release20 mg/1OralProficient Rx2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release40 mg/1OralAphena Pharma Solutions Tennessee, Llc2008-01-31Not applicableUs
Pantoprazole Sodium Delayed-releaseTablet, delayed release40 mg/1OralCardinal Health2008-01-312016-03-22Us
Pantoprazole Sodium Delayed-releaseTablet, delayed release40 mg/1OralContract Pharmacy Services Pa2010-02-26Not applicableUs
Pantoprazole Sodium Delayed-release Delayed-releaseTablet, delayed release40 mg/1OralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Pantoprazole Sodium for InjectionPowder, for solution40 mgIntravenousSandoz Canada Incorporated2008-03-11Not applicableCanada
Pantoprazole Sodium for InjectionPowder, for solution40 mgIntravenousGeneric Medical Partners IncNot applicableNot applicableCanada
Pantoprazole Sodium for InjectionPowder, for solution40 mgIntravenousAccord Healthcare IncNot applicableNot applicableCanada
Pantoprazole Sodium for InjectionPowder, for solution40 mgIntravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Pantoprazole Sodiumdelayed-release Delayed-releaseTablet, delayed release40 mg/1OralPd Rx Pharmaceuticals, Inc.2008-01-31Not applicableUs
Pantoprazole-20Tablet, delayed release20 mgOralSivem Pharmaceuticals Ulc2014-07-21Not applicableCanada
Pantoprazole-40Tablet, delayed release40 mgOralSivem Pharmaceuticals Ulc2014-07-21Not applicableCanada
Pantozol ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantozol ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantozol ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Pantozol ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
PHL-pantoprazolePowder, for solution40 mgIntravenousPharmel IncNot applicableNot applicableCanada
PMS-pantoprazolePowder, for solution40 mgIntravenousPharmascience Inc2007-04-03Not applicableCanada
PMS-pantoprazoleTablet, delayed release20 mgOralPharmascience Inc2008-06-04Not applicableCanada
PMS-pantoprazoleTablet, delayed release40 mgOralPharmascience Inc2008-06-04Not applicableCanada
Priva-pantoprazoleTablet, delayed release40 mgOralPharmapar Inc2015-01-13Not applicableCanada
ProtonixTablet, delayed release40 mg/1OralRebel Distributors Corp2001-08-28Not applicableUs
Protonix Delayed-releaseGranule, delayed release40 mg/1OralCardinal Health2008-02-29Not applicableUs
Protonix Delayed-releaseTablet, delayed release20 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
Protonix Delayed-releaseGranule, delayed release40 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2008-02-29Not applicableUs
Protonix Delayed-releaseTablet, delayed release40 mg/1OralAvera Mc Kennan Hospital2015-09-21Not applicableUs
Protonix Delayed-releaseTablet, delayed release40 mg/1OralPhysicians Total Care, Inc.2001-08-28Not applicableUs
Protonix Delayed-releaseTablet, delayed release20 mg/1OralCardinal Health2000-05-01Not applicableUs
Protonix Delayed-releaseTablet, delayed release20 mg/1OralPhysicians Total Care, Inc.2003-05-02Not applicableUs
Protonix Delayed-releaseTablet, delayed release40 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2000-05-01Not applicableUs
Protonix Delayed-releaseTablet, delayed release20 mg/1OralSTAT Rx USA LLC2000-05-01Not applicableUs
Protonix Delayed-releaseTablet, delayed release40 mg/1OralCardinal Health2000-05-01Not applicableUs
Protonix Delayed-releaseTablet, delayed release20 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2000-05-01Not applicableUs
Protonix Delayed-releaseTablet, delayed release40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
Protonix I.V.Injection, powder, for solution40 mg/10mLIntravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2014-03-17Not applicableUs
Protonix I.V.Injection, powder, for solution40 mg/10mLIntravenousCardinal Health2001-05-01Not applicableUs
Protonix I.V.Injection, powder, for solution40 mg/10mLIntravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2013-05-01Not applicableUs
Protonix I.V.Injection, powder, for solution40 mg/10mLIntravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2001-05-01Not applicableUs
Protonix I.V.Injection, powder, for solution40 mg/10mLIntravenousCardinal Health2001-05-01Not applicableUs
Protonix I.V.Injection, powder, for solution40 mg/10mLIntravenousWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2001-05-01Not applicableUs
Protonix I.V.Injection, powder, for solution40 mg/10mLIntravenousCardinal Health2001-05-01Not applicableUs
Q-pantoprazoleTablet, delayed release40 mgOralQd Pharmaceuticals Ulc2011-10-032015-08-21Canada
Ran-pantoprazoleTablet, delayed release20 mgOralRanbaxy Pharmaceuticals Canada Inc.2008-02-12Not applicableCanada
Ran-pantoprazoleTablet, delayed release40 mgOralRanbaxy Pharmaceuticals Canada Inc.2008-02-12Not applicableCanada
Ratio-pantoprazoleTablet, delayed release40 mgOralRatiopharm Inc Division Of Teva Canada Limited2008-06-032015-10-26Canada
Ratio-pantoprazoleTablet, delayed release20 mgOralRatiopharm Inc Division Of Teva Canada Limited2008-06-032015-10-26Canada
Riva-pantoprazoleTablet, delayed release40 mgOralLaboratoire Riva Inc2008-10-27Not applicableCanada
Riva-pantoprazoleTablet, delayed release20 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Sandoz PantoprazoleTablet, delayed release20 mgOralSandoz Canada Incorporated2008-06-03Not applicableCanada
Sandoz PantoprazoleTablet, delayed release40 mgOralSandoz Canada Incorporated2008-06-03Not applicableCanada
Somac ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Somac ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Somac ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
Somac ControlTablet, delayed release20 mgOralTakeda Gmb H2009-06-12Not applicableEu
TectaTablet, delayed release40 mgOralTakeda Canada Inc2006-03-15Not applicableCanada
Teva-pantoprazoleTablet, delayed release40 mgOralTeva Canada Limited2008-04-11Not applicableCanada
Teva-pantoprazoleTablet, delayed release20 mgOralTeva Canada Limited2008-04-11Not applicableCanada
Teva-pantoprazole MagnesiumTablet, delayed release40 mgOralTeva Canada Limited2015-11-16Not applicableCanada
Torrent-pantoprazoleTablet, delayed release40 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-pantoprazoleTablet, delayed release20 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-pantoprazoleTablet, delayed release40 mgOralVanc Pharmaceuticals Inc2015-11-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pantoprazoleTablet, delayed release20 mgOralApotex Inc2008-03-05Not applicableCanada
Apo-pantoprazoleTablet, delayed release40 mgOralApotex Inc2008-03-05Not applicableCanada
PantoprazoleTablet, delayed release20 mg/1OralDr.Reddy's Laboratories Limited2011-01-19Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralDr.Reddy's Laboratories Limited2011-01-19Not applicableUs
PantoprazoleTablet, delayed release20 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralMajor Pharmaceuticals2011-01-19Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralLegacy Pharmaceutical Packaging2011-01-19Not applicableUs
PantoprazoleTablet, delayed release40 mg/1OralCardinal Health2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralWockhardt Limited2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralKremers Urban Pharmaceuticals Inc.2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralProficient Rx LP2007-12-19Not applicableUs
Pantoprazole SodiumTablet40 mg/1OralREMEDYREPACK INC.2011-11-152016-10-13Us
Pantoprazole SodiumTablet, delayed release40 mg/1OralLegacy Pharmaceutical Packaging2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole SodiumInjection, powder, for solution40 mg/1IntravenousAuro Medics Pharma Llc2016-03-30Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralA S Medication Solutions2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2014-02-18Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralRebel Distributors Corp2010-10-12Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralLegacy Pharmaceutical Packaging, Llc2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2014-12-26Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAphena Pharma Solutions Tennessee, Inc.2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralWockhardt USA LLC.2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2015-02-24Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralAvera Mc Kennan Hospital2015-03-18Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-01-23Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAv Pak2015-01-30Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralUnit Dose Services2014-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralAurobindo Pharma Limited2012-09-28Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralOrchid Pharma Inc2015-03-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1Oralbryant ranch prepack2007-12-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralUnit Dose Services2007-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAmerican Health Packaging2013-05-152015-12-29Us
Pantoprazole SodiumTablet, delayed release40 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralAmerican Health Packaging2013-08-26Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2014-04-24Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAv Kare, Inc.2016-02-22Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralCardinal Health2015-06-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralA S Medication Solutions2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralTorrent Pharmaceuticals Limited2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralCardinal Health2012-09-05Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralMacleods Pharmaceuticals Limited2011-12-03Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralSun Pharma Global FZE2007-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-04-10Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralKremers Urban Pharmaceuticals Inc.2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralProficient Rx LP2007-12-21Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2011-12-02Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralLegacy Pharmaceutical Packaging, Llc2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralCamber Pharmaceuticals, Inc.2014-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralA S Medication Solutions2007-12-21Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2014-03-05Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralRx Change Co.2007-12-21Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2016-11-22Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2015-01-12Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralMedsource Pharmaceuticals2007-12-21Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralWockhardt USA LLC.2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2013-05-24Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralCardinal Health2015-05-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2015-10-09Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralPreferred Pharmaceuticals Inc.2016-10-18Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-21Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1Oralbryant ranch prepack2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralUnit Dose Services2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralAmerican Health Packaging2012-03-012016-01-01Us
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2013-01-10Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralA S Medication Solutions2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAurobindo Pharma Limited2012-09-28Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralOrchid Pharma Inc2015-03-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralJubilant Cadista Pharmaceuticals Inc.2011-09-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralMacleods Pharmaceuticals Limited2011-12-03Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAmerican Health Packaging2014-12-16Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2014-06-11Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralProficient Rx LP2014-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralActavis Pharma, Inc.2011-02-082016-12-31Us
Pantoprazole SodiumTablet, delayed release40 mg/1OralTorrent Pharmaceuticals Limited2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralCardinal Health2012-01-23Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralRanbaxy Pharmaceuticals Inc.2012-05-02Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2013-02-082016-10-13Us
Pantoprazole SodiumTablet, delayed release40 mg/1OralLegacy Pharmaceutical Packaging, Llc2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralCamber Pharmaceuticals, Inc.2014-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralA S Medication Solutions2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2013-11-18Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralCardinal Health2011-02-07Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-12-21Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralDIRECT RX2014-01-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralActavis Inc.2011-02-082016-11-08Us
Pantoprazole SodiumTablet, delayed release20 mg/1OralPrasco Laboratories2015-05-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2014-02-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralLegacy Pharmaceutical Packaging, Llc2011-01-202016-02-29Us
Pantoprazole SodiumTablet, delayed release40 mg/1OralPreferred Pharmaceuticals, Inc.2014-12-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralDIRECT RX2014-01-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralMylan Institutional Inc.2011-02-23Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralPhysicians Total Care, Inc.2008-01-02Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralCardinal Health2013-01-15Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralMylan Pharmaceuticals Inc.2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralRebel Distributors Corp2007-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2011-09-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralKremers Urban Pharmaceuticals Inc.2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralProficient Rx LP2011-02-08Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2011-11-15Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralREMEDYREPACK INC.2015-09-04Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAphena Pharma Solutions Tennessee, Llc2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2011-01-20Not applicableUs
Pantoprazole SodiumInjection, powder, for solution40 mg/1IntravenousAkorn, Inc.2012-11-082016-02-05Us
Pantoprazole SodiumTablet, delayed release20 mg/1OralWockhardt Limited2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2013-08-22Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralClinical Solutions Wholesale, Llc2007-12-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralRanbaxy Pharmaceuticals Inc.2012-05-02Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAv Pak2013-01-152016-10-13Us
Pantoprazole SodiumTablet, delayed release20 mg/1OralAmerican Health Packaging2013-05-152015-12-29Us
Pantoprazole SodiumTablet, delayed release40 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralAv Pak2013-01-15Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralA S Medication Solutions2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2014-12-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralA S Medication Solutions2014-12-15Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralMajor Pharmaceuticals2015-06-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralTeva Pharmaceuticals Usa, Inc.2007-12-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralDIRECT RX2015-01-01Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralSun Pharma Global FZE2007-09-10Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralPrasco Laboratories2015-05-01Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralREMEDYREPACK INC.2014-02-182016-04-05Us
Pantoprazole SodiumTablet, delayed release20 mg/1OralAv Kare, Inc.2016-02-22Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralSt Marys Medical Park Pharmacy2013-08-08Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralReady Meds2011-01-20Not applicableUs
Pantoprazole SodiumTablet, delayed release20 mg/1OralPhysicians Total Care, Inc.2009-06-03Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralClinical Solutions Wholesale2011-02-08Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralMylan Pharmaceuticals Inc.2011-01-19Not applicableUs
Pantoprazole SodiumTablet, delayed release40 mg/1OralPd Rx Pharmaceuticals, Inc.2015-05-01Not applicableUs
Pantoprazole Sodium Delayed ReleaseTablet40 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Pantoprazole Sodium Delayed ReleaseTablet, delayed release40 mg/1OralNorthwind Pharmaceuticals2014-03-21Not applicableUs
Pantoprazole Sodium DrTablet, delayed release40 mg/1OralNorthwind Pharmaceuticals, LLC2014-07-16Not applicableUs
Pantoprazole Sodium DrTablet, delayed release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PantozolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pantoprazole magnesium
199387-73-0
Thumb
  • InChI Key: RDRUTBCDIVCMMX-UHFFFAOYSA-N
  • Monoisotopic Mass: 788.11965859
  • Average Mass: 789.03
DBSALT000853
Pantoprazole magnesium hemipentahydrate
ThumbNot applicableDBSALT001960
Pantoprazole sodium
138786-67-1
Thumb
  • InChI Key: YNWDKZIIWCEDEE-UHFFFAOYNA-N
  • Monoisotopic Mass: 405.057077726
  • Average Mass: 405.352
DBSALT000386
Categories
UNIID8TST4O562
CAS number102625-70-7
WeightAverage: 383.37
Monoisotopic: 383.075133083
Chemical FormulaC16H15F2N3O4S
InChI KeyIQPSEEYGBUAQFF-UHFFFAOYSA-N
InChI
InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
IUPAC Name
6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1
Pharmacology
IndicationShort-term (up to 16 weeks) treatment of erosive esophagitis.
Structured Indications
PharmacodynamicsPantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production.
Mechanism of actionPantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+,K+ )- ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose- related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium-transporting ATPase alpha chain 1Proteinyes
inhibitor
HumanP20648 details
Related Articles
AbsorptionPantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%.
Volume of distribution
  • 11.0 to 23.6 L
Protein binding98%
Metabolism

Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity.

SubstrateEnzymesProduct
Pantoprazole
Not Available
Active Metabolite of PantoprazoleDetails
Route of eliminationAfter administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer subjects, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion.
Half life1 hour
Clearance
  • 7.6-14.0 L/h
ToxicitySingle intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of toxicity included hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor. There is limited experience regarding cases of human overdosage, and treatment should be symptomatic and supportive.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pantoprazole Action PathwayDrug actionSMP00228
Pantoprazole Metabolism PathwayDrug metabolismSMP00615
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Pantoprazole can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Pantoprazole.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Pantoprazole.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Pantoprazole.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Pantoprazole.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Pantoprazole.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Pantoprazole.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Pantoprazole.Experimental
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Pantoprazole.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pantoprazole.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Pantoprazole.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Pantoprazole.Approved, Withdrawn
AmiodaroneThe metabolism of Pantoprazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Pantoprazole.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Pantoprazole.Approved, Vet Approved
AmphetaminePantoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Pantoprazole.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Pantoprazole.Approved
AprepitantThe serum concentration of Pantoprazole can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Pantoprazole.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.Approved, Investigational
ArmodafinilThe metabolism of Pantoprazole can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Pantoprazole.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Pantoprazole.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Pantoprazole.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Pantoprazole.Approved
AtomoxetineThe metabolism of Pantoprazole can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Pantoprazole.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Pantoprazole.Approved
AzithromycinThe metabolism of Pantoprazole can be decreased when combined with Azithromycin.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Pantoprazole.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Pantoprazole.Approved, Vet Approved
BexaroteneThe serum concentration of Pantoprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Pantoprazole can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Pantoprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pantoprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Pantoprazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pantoprazole.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Pantoprazole.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Pantoprazole.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Pantoprazole.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Pantoprazole.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Pantoprazole.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Pantoprazole.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Pantoprazole.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Pantoprazole.Approved
CarbamazepineThe metabolism of Pantoprazole can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Pantoprazole.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Pantoprazole.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Pantoprazole.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Pantoprazole.Approved
CeritinibThe serum concentration of Pantoprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Pantoprazole.Withdrawn
ChloramphenicolThe metabolism of Pantoprazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Pantoprazole.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Pantoprazole.Approved
CholecalciferolThe metabolism of Pantoprazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Pantoprazole.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Pantoprazole.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Pantoprazole.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Pantoprazole.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Pantoprazole.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Pantoprazole.Approved
ClarithromycinThe metabolism of Pantoprazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pantoprazole can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Pantoprazole.Approved, Illicit
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Pantoprazole.Approved, Investigational, Vet Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Pantoprazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Pantoprazole.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Pantoprazole.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Pantoprazole.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Pantoprazole resulting in a loss in efficacy.Approved, Nutraceutical
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Pantoprazole.Approved, Illicit
ClotrimazoleThe metabolism of Pantoprazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Pantoprazole.Approved
CobicistatThe metabolism of Pantoprazole can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Pantoprazole.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Pantoprazole.Approved
ConivaptanThe serum concentration of Pantoprazole can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pantoprazole.Approved
CrizotinibThe metabolism of Pantoprazole can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Pantoprazole.Approved, Investigational
CyclosporineThe metabolism of Pantoprazole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pantoprazole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Pantoprazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pantoprazole.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Pantoprazole.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Pantoprazole.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Pantoprazole.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Pantoprazole.Approved, Investigational
DarunavirThe metabolism of Pantoprazole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Pantoprazole.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Pantoprazole.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Pantoprazole.Approved
DeferasiroxThe serum concentration of Pantoprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Pantoprazole.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Pantoprazole.Approved
DexamethasoneThe serum concentration of Pantoprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmethylphenidatePantoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetaminePantoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Pantoprazole.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Pantoprazole.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Pantoprazole.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pantoprazole.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Pantoprazole.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pantoprazole.Approved
DihydroergotamineThe metabolism of Pantoprazole can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Pantoprazole.Illicit
DiltiazemThe metabolism of Pantoprazole can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Pantoprazole.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Pantoprazole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Pantoprazole.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Pantoprazole.Approved, Investigational, Vet Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Pantoprazole.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Pantoprazole.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Pantoprazole.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Pantoprazole.Approved, Investigational
DoxycyclineThe metabolism of Pantoprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe metabolism of Dronabinol can be decreased when combined with Pantoprazole.Approved, Illicit
DronedaroneThe metabolism of Pantoprazole can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Pantoprazole.Approved
EfavirenzThe serum concentration of Pantoprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Pantoprazole.Approved, Investigational
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Pantoprazole.Approved, Investigational
EnzalutamideThe serum concentration of Pantoprazole can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Pantoprazole.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Pantoprazole.Approved, Investigational
ErythromycinThe metabolism of Pantoprazole can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Pantoprazole.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Pantoprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Pantoprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Pantoprazole.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Pantoprazole.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Pantoprazole.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pantoprazole.Approved
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Pantoprazole.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Pantoprazole.Approved
EtravirineThe serum concentration of Pantoprazole can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Pantoprazole.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Pantoprazole.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Pantoprazole.Approved
Ferric CarboxymaltosePantoprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitratePantoprazole can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphatePantoprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Pantoprazole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Pantoprazole.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Pantoprazole.Approved
FluconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Fluconazole.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Pantoprazole.Approved, Illicit
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Pantoprazole.Approved, Vet Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Pantoprazole.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Pantoprazole.Approved
FluvoxamineThe metabolism of Pantoprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Pantoprazole.Approved, Investigational
FosamprenavirThe metabolism of Pantoprazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pantoprazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Pantoprazole can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Pantoprazole can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Pantoprazole.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Pantoprazole.Approved
GemfibrozilThe metabolism of Pantoprazole can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Pantoprazole.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Pantoprazole.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Pantoprazole.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Pantoprazole.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Pantoprazole.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Pantoprazole.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Pantoprazole.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Pantoprazole.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Pantoprazole.Approved, Vet Approved
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Pantoprazole.Approved
IdelalisibThe serum concentration of Pantoprazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Pantoprazole.Approved
ImatinibThe metabolism of Pantoprazole can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Pantoprazole.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Pantoprazole.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Pantoprazole.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Pantoprazole.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Pantoprazole.Approved, Investigational
IronPantoprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranPantoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharatePantoprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe metabolism of Pantoprazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Pantoprazole can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Pantoprazole can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Pantoprazole.Approved, Investigational
IvacaftorThe serum concentration of Pantoprazole can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Pantoprazole.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Pantoprazole.Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Pantoprazole.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Pantoprazole.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Pantoprazole.Approved, Investigational
KetoconazoleThe metabolism of Pantoprazole can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Pantoprazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Pantoprazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Pantoprazole.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Pantoprazole.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Pantoprazole.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Pantoprazole.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Pantoprazole.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Pantoprazole.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Pantoprazole.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Pantoprazole.Approved
LidocaineThe metabolism of Pantoprazole can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Pantoprazole.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Pantoprazole.Approved
LopinavirThe metabolism of Pantoprazole can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Pantoprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Pantoprazole.Approved
LovastatinThe metabolism of Pantoprazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pantoprazole can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Pantoprazole.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Pantoprazole.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Pantoprazole.Approved, Investigational
MelatoninThe metabolism of Melatonin can be decreased when combined with Pantoprazole.Approved, Nutraceutical, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Pantoprazole.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Pantoprazole.Approved, Illicit
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Pantoprazole.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Pantoprazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pantoprazole.Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Pantoprazole.Approved
MethylphenidatePantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Pantoprazole.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Pantoprazole.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pantoprazole.Approved, Investigational
MexiletineThe metabolism of Pantoprazole can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Pantoprazole.Approved, Illicit
MifepristoneThe serum concentration of Pantoprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Pantoprazole.Approved
MitotaneThe serum concentration of Pantoprazole can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Pantoprazole.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Pantoprazole.Approved
ModafinilThe serum concentration of Pantoprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Pantoprazole.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pantoprazole.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Pantoprazole.Approved
NafcillinThe serum concentration of Pantoprazole can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Pantoprazole.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Pantoprazole.Approved, Vet Approved
NefazodoneThe metabolism of Pantoprazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Pantoprazole resulting in a loss in efficacy.Approved
NetupitantThe serum concentration of Pantoprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Pantoprazole can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Pantoprazole.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Pantoprazole.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Pantoprazole.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Pantoprazole.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Pantoprazole.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Pantoprazole.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Pantoprazole.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Pantoprazole.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Pantoprazole.Approved, Investigational
OlaparibThe metabolism of Pantoprazole can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Pantoprazole.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Pantoprazole can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Pantoprazole.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Pantoprazole.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Pantoprazole.Approved, Vet Approved
PalbociclibThe serum concentration of Pantoprazole can be increased when it is combined with Palbociclib.Approved
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Pantoprazole.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Pantoprazole.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Pantoprazole.Approved
Peginterferon alfa-2bThe serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Pantoprazole.Approved
PentobarbitalThe metabolism of Pantoprazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Pantoprazole.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Pantoprazole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Pantoprazole.Withdrawn
PhenobarbitalThe metabolism of Pantoprazole can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Pantoprazole can be increased when combined with Phenytoin.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Pantoprazole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Pantoprazole.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Pantoprazole.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Pantoprazole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Pantoprazole.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Pantoprazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Pantoprazole.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Pantoprazole.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Pantoprazole.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Pantoprazole.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Pantoprazole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Pantoprazole.Approved, Vet Approved
PrimidoneThe metabolism of Pantoprazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Pantoprazole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Pantoprazole.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Pantoprazole.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Pantoprazole.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Pantoprazole.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Pantoprazole.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Pantoprazole.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Pantoprazole.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Pantoprazole.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Pantoprazole.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Pantoprazole.Approved
RamelteonThe metabolism of Ramelteon can be decreased when combined with Pantoprazole.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Pantoprazole.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Pantoprazole.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Pantoprazole.Approved
RifabutinThe metabolism of Pantoprazole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Pantoprazole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pantoprazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pantoprazole.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Pantoprazole.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Pantoprazole.Approved
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Pantoprazole.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Pantoprazole.Approved, Investigational
RitonavirThe metabolism of Pantoprazole can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Pantoprazole.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Pantoprazole.Approved, Investigational
RopiniroleThe metabolism of Pantoprazole can be decreased when combined with Ropinirole.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Pantoprazole.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Pantoprazole.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Pantoprazole.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Pantoprazole.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Pantoprazole.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Pantoprazole.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Pantoprazole.Approved
SildenafilThe metabolism of Pantoprazole can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Pantoprazole.Approved
SiltuximabThe serum concentration of Pantoprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pantoprazole can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Pantoprazole.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Pantoprazole.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Pantoprazole.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Pantoprazole.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Pantoprazole.Experimental
St. John's WortThe serum concentration of Pantoprazole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Pantoprazole can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Pantoprazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Pantoprazole.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Pantoprazole.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Pantoprazole.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Pantoprazole.Experimental
Technetium tc 99m etidronateThe therapeutic efficacy of Technetium tc 99m etidronate can be decreased when used in combination with Pantoprazole.Approved
Technetium Tc-99m MedronateThe therapeutic efficacy of Technetium Tc-99m Medronate can be decreased when used in combination with Pantoprazole.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pantoprazole.Approved
TelaprevirThe metabolism of Pantoprazole can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Pantoprazole can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Pantoprazole.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Pantoprazole.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Pantoprazole.Approved
TenofovirThe metabolism of Pantoprazole can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Pantoprazole.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Pantoprazole can be decreased when it is combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Pantoprazole.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Pantoprazole.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Pantoprazole can be decreased when combined with Theophylline.Approved
ThioridazineThe metabolism of Thioridazine can be decreased when combined with Pantoprazole.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Pantoprazole.Approved
TiclopidineThe metabolism of Pantoprazole can be decreased when combined with Ticlopidine.Approved
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Pantoprazole.Approved, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Pantoprazole.Approved
TipranavirThe serum concentration of Pantoprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Pantoprazole can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Pantoprazole.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Pantoprazole.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Pantoprazole.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Pantoprazole.Approved
TopiramateThe metabolism of Pantoprazole can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Pantoprazole.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Pantoprazole.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Pantoprazole.Approved, Investigational
TranylcypromineThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Pantoprazole.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Pantoprazole.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Pantoprazole.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Pantoprazole.Withdrawn
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Pantoprazole.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Pantoprazole.Approved
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Pantoprazole.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Pantoprazole.Approved
VemurafenibThe serum concentration of Pantoprazole can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Pantoprazole.Approved
VenlafaxineThe metabolism of Pantoprazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Pantoprazole can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Pantoprazole.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Pantoprazole.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Pantoprazole.Approved
VoriconazoleThe serum concentration of Pantoprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pantoprazole.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Pantoprazole.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Pantoprazole.Approved
ZiprasidoneThe metabolism of Pantoprazole can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Pantoprazole.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Pantoprazole.Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Rudolf Linder, “Freeze-dried pantoprazole preparation and pantoprazole injection.” U.S. Patent US20030003058, issued January 02, 2003.

US20030003058
General ReferencesNot Available
External Links
ATC CodesA02BC02A02BD11A02BD04
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (183 KB)
MSDSDownload (58.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier-0.5777
Caco-2 permeable+0.7262
P-glycoprotein substrateNon-substrate0.6127
P-glycoprotein inhibitor IInhibitor0.5587
P-glycoprotein inhibitor IINon-inhibitor0.9198
Renal organic cation transporterNon-inhibitor0.6285
CYP450 2C9 substrateNon-substrate0.84
CYP450 2D6 substrateNon-substrate0.8683
CYP450 3A4 substrateSubstrate0.7254
CYP450 1A2 substrateInhibitor0.7639
CYP450 2C9 inhibitorNon-inhibitor0.8054
CYP450 2D6 inhibitorNon-inhibitor0.7308
CYP450 2C19 inhibitorInhibitor0.7877
CYP450 3A4 inhibitorNon-inhibitor0.7258
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.903
Ames testNon AMES toxic0.5527
CarcinogenicityNon-carcinogens0.8108
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.3466 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9228
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth pharmaceuticals inc
  • Kudco ireland ltd
  • Sun pharma global inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous40 mg
Tablet, delayed releaseOral20 mg
Tablet, delayed releaseOral40 mg
Injection, powder, for solutionIntravenous40 mg/1
TabletOral40 mg/1
Tablet, delayed releaseOral20 mg/1
Tablet, delayed releaseOral40 mg/1
Granule, delayed releaseOral40 mg/1
Injection, powder, for solutionIntravenous40 mg/10mL
Prices
Unit descriptionCostUnit
Protonix iv 40 mg vial14.4USD vial
Protonix 40 mg tablet dr8.91USD tablet
Protonix 20 mg tablet5.43USD tab
Protonix 40 mg Enteric Coated Tabs5.43USD tab
Protonix dr 20 mg tablet5.22USD tablet
Protonix dr 40 mg tablet5.22USD tablet
Pantoprazole Sodium 20 mg Enteric Coated Tabs4.26USD tab
Pantoprazole Sodium 40 mg Enteric Coated Tabs4.26USD tab
Pantoprazole sod dr 20 mg tablet3.93USD tablet
Pantoprazole sod dr 40 mg tablet3.93USD tablet
Pantoloc 40 mg Enteric-Coated Tablet2.28USD tablet
Apo-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Co Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Mylan-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Novo-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Phl-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Pms-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Ran-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Ratio-Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
Sandoz Pantoprazole 40 mg Enteric-Coated Tablet1.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2092694 No2005-04-052011-09-06Canada
CA2341031 No2006-04-042019-08-12Canada
CA2428870 No2006-05-232021-11-17Canada
US4758579 No1993-07-192010-07-19Us
US5997903 Yes1997-06-072017-06-07Us
US6780881 Yes2002-05-172022-05-17Us
US7351723 Yes2002-05-172022-05-17Us
US7544370 Yes2006-12-072026-12-07Us
US7550153 Yes2005-03-302025-03-30Us
US7553498 Yes2005-03-302025-03-30Us
US7838027 Yes2005-03-302025-03-30Us
US8754108 Yes2002-05-172022-05-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting pointBecause of gradual degradation of pantoprazole sodium during heating, the melting point cannot be determined.Not Available
water solubilityFreely soluble in water.Not Available
logP0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.495 mg/mLALOGPS
logP2.11ALOGPS
logP2.18ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)9.15ChemAxon
pKa (Strongest Basic)3.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.33 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.05 m3·mol-1ChemAxon
Polarizability35.17 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Halomethane
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Moreira Dias L: Pantoprazole: a proton pump inhibitor. Clin Drug Investig. 2009;29 Suppl 2:3-12. doi: 10.2165/1153121-S0-000000000-00000. [PubMed:19938880 ]
  2. Cheer SM, Prakash A, Faulds D, Lamb HM: Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101-33. [PubMed:12487624 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923 ]
  2. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
  3. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [PubMed:19139163 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 04:00